

<u>EMA number</u>	<u>(Invented) name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Immediate Packaging</u>	<u>Content (concentration)</u>	<u>Pack size</u>
EMA/H/W/002300/001	Mosquirix	... ^{1*}	Powder and suspension for suspension for injection	Intramuscular use	Powder: vial (glass) suspension: vial (glass)	Powder 25 µg Suspension: 1 ml	50 powder vials + 50 suspension vials

1*

After reconstitution, 1 dose (0.5 ml) contains 25 micrograms of RTS,S^{1,2} adjuvanted with AS01_E³.

¹ Portion of *P. falciparum* circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)

² in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (*Saccharomyces cerevisiae*) by recombinant DNA technology

³ AS01_E adjuvant is composed of *Quillaja saponaria* Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) (25 micrograms)